Elevated Serum Growth Differentiation Factor 15 Levels as a Potential Biomarker of the Efficacy of Imeglimin in Individuals With Type 2 Diabetes Mellitus: An Exploratory Study

Authors

  • Naoki Wada Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine, Kyoto University Kyoto, Japan.
  • Takaaki Murakami Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine, Kyoto University Kyoto, Japan. https://orcid.org/0000-0003-3844-1138
  • Muhammad Fauzi Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine, Kyoto University Kyoto, Japan.
  • Kentaro Sakaki Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine, Kyoto University Kyoto, Japan.
  • Shinobu Oshima Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Yoshihito Shimada Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Kanae Asai Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Ayako Oshima Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Satoko Nomura Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Erina Joo Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Michiko Mori Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Ryoko Fujiwara Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Kenichiro Shide Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Keiko Wada Department of Metabolism and Clinical Nutrition, Kyoto University Hospital Kyoto, Japan.
  • Daisuke Yabe Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine, Kyoto University Kyoto, Japan. https://orcid.org/0000-0002-5334-7687
  • Nobuya Inagaki Medical Research Institute KITANO HOSPITAL, P.I.I.F. Tazuke-Kofukai, Osaka, Japan. https://orcid.org/0000-0001-8261-2593
  • Norio Harada Department of Endocrinology and Metabolism, School of Medical Sciences, University of Fukui, Japan. https://orcid.org/0000-0001-8720-1013

DOI:

https://doi.org/10.14740/jocmr6031

Keywords:

GDF15, Imeglimin, Diabetes mellitus

Abstract

Background: The aim of the present study was to conduct a prospective observational study to explore the effects of imeglimin on systemic energy metabolism/body composition and to identify potential mitochondria-related biomarkers of the efficacy of the drug in clinical settings.

Methods: In this prospective observational study, 16 participants with type 2 diabetes mellitus in the diabetes clinic of Kyoto University Hospital were enrolled. Individuals were started on imeglimin as monotherapy or add-on therapy.

Results: After 3 months under imeglimin treatment, there was no significant change in basal metabolism or body composition. However, serum levels of growth differentiation factor 15 (GDF15) were higher while those of serum fibroblast growth factor 21 and urine 8-hydroxy-2′-deoxyguanosine were not changed. Additional in vitro examination revealed that imeglimin induces GDF15 protein release from human hepatocytes.

Conclusions: Three-month imeglimin treatment increased serum GDF15 levels in clinical type 2 diabetes mellitus patients along with little change in basal metabolism or body composition, suggesting GDF15 as a potential marker for the efficacy of imeglimin.

6031

Downloads

Published

2024-10-31

Issue

Vol. 16, No. 10, Oct 2024

Section

Short Communication

License

Copyright (c) 2024 Journal of Clinical Medicine Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Wada, N., Murakami, T., Fauzi, M., Sakaki, K., Oshima, S., Shimada, Y., Asai, K., Oshima, A., Nomura, S., Joo, E., Mori, M., Fujiwara, R., Shide, K., Wada, K., Yabe, D., Inagaki, N., & Harada, N. (2024). Elevated Serum Growth Differentiation Factor 15 Levels as a Potential Biomarker of the Efficacy of Imeglimin in Individuals With Type 2 Diabetes Mellitus: An Exploratory Study. Journal of Clinical Medicine Research, 16(10), 503-508. https://doi.org/10.14740/jocmr6031